Home Blog Page 1828

Entrepreneur Universe Bright Group Reports Third Quarter 2025 Financial Results

By
Advertorial Desk
-

XI’AN, China, Nov. 13, 2025 /PRNewswire/ — Entrepreneur Universe Bright Group (“EUBG” or the “Company”), a Nevada corporation, today announced its unaudited financial results for the quarter ended September 30, 2025.

Financial Highlights

  • Revenue: USD 1,217,966 for the three months ended September 30, 2025, compared to USD 1,670,203 for the three months ended September 30, 2024, representing a 27% decrease.
  • Gross Profit: USD 1,080,656 for the three months ended September 30, 2025, compared to USD 1,490,851 for the three months ended September 30, 2024, a decrease of 28%.
  • Net Income: USD 395,113 for the three months ended September 30, 2025, compared to USD 703,615 for the three months ended September 30, 2024, representing a 44% decrease.
  • Total Comprehensive Income: USD 477,097 for the three months ended September 30, 2025, compared to USD 872,508 for the three months ended September 30, 2024, representing a 45% decrease.
  • Cash Position: Cash and cash equivalents were approximately USD 9.56 million as of September 30, 2025.
  • Total Assets: USD 10.29 million as of September 30, 2025, compared with USD 9.39 million as of December 31, 2024.

Business Overview
EUBG provides digital marketing consultancy services through its wholly-owned PRC subsidiary, Xi’an Yunchuang Space Information Technology Co., Ltd., and its Hong Kong subsidiary. The Company helps startups and small businesses enhance brand visibility and improve sales through online platforms. EUBG does not use any VIE structure, and all operations are conducted through directly held subsidiaries in Hong Kong SAR and Mainland China.

Strategic Outlook
EUBG remains focused on expanding high-value digital advisory and data-driven marketing solutions to better serve clients in China’s rapidly evolving digital economy. The Company aims to strengthen service offerings in brand consulting, omni-channel e-commerce integration, and performance-based marketing campaigns. In addition, EUBG remains committed to maintaining robust cash flow discipline and full compliance with both PRC and U.S. regulatory frameworks.

Management Commentary
Mr. Guolin Tao, CEO of EUBG, stated:

“During the third quarter, we continued to operate prudently under a dynamic market environment. While revenues reflected temporary softness in client budgets, our underlying cash generation and balance sheet remained strong. We will continue to uphold compliance discipline, maintain financial flexibility, and deliver long-term value to our shareholders.”

About Entrepreneur Universe Bright Group
Entrepreneur Universe Bright Group is a Nevada-based holding company that conducts its operations through its wholly-owned subsidiaries in Hong Kong SAR and Mainland China. The Company primarily engages in consulting, sourcing, and digital marketing services to support business clients across multiple industries. For more information, please visit: www.eubggroup.com.

Safe Harbor Statement
This press release contains projections and “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995 related to the Company’s business. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are not historical facts. When the Company uses words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate,” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements.

Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause actual results to differ materially from those discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to: the Company’s goals and strategies; future business development; financial condition and results of operations; product and service demand and acceptance; competition and pricing pressures; changes in technology; government regulations; fluctuations in economic and business conditions in China; and assumptions underlying or related to any of the foregoing and other risks contained in the Company’s filings with the SEC. Investors are cautioned not to place undue reliance on any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, available at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect subsequent events or circumstances.

 

GAR Continues Record-Breaking Financial Results Run With Nine-Month Revenue High

By
Advertorial Desk
-
  • Company builds on first half performance to reach record nine-month revenue of US$9.53 billion, up 21% year-on-year
  • Higher plantation output helped the Company capitalise on CPO price increase
  • EBITDA for the first nine months of 2025 rose by 16% to US$882 million, with recovery in downstream merchandising volume complementing upstream performance.

SINGAPORE, Nov. 13, 2025 /PRNewswire/ — Golden Agri-Resources Ltd (“GAR” or the “Company”) continued its run of record-high revenue for a second consecutive quarter, recording US$9.53 billion for the nine-month period of 2025. Higher plantation output helped the Company capitalise on a 17% rise in crude palm oil (“CPO”) prices (FOB Belawan), while a modest increase in downstream volume further supported revenue growth.

GAR recorded record-high revenue for the first nine months of 2025; continuing its first-half record revenue trend.
GAR recorded record-high revenue for the first nine months of 2025; continuing its first-half record revenue trend.

Nine-month EBITDA grew by 16% to reach US$882 million, preserving a healthy margin of 9.3%. Foreign exchange loss increased from US$2 million in the same period last year to US$15 million. Net profit remained strong, growing by 29% to reach US$284 million.

GAR’s balance sheet has also been strengthened, with an improved gearing ratio of 0.56 times and a much lower net debt to EBITDA ratio of 0.10 times.

On the outlook, Mr. Franky O. Widjaja, GAR Chairman and Chief Executive Officer commented: “Vegetable oil industry fundamentals remain robust, driven by steady and rising global demand. Limitations in supply growth capability, often compounded by unfavourable weather conditions, present ongoing challenges to meeting this demand. For palm oil, short- and medium-term supply growth has been constrained by ageing plantations and replanting activity which provide support to CPO prices. The market is also paying close attention to any changes in biofuel blending mandates across the world. Any shifts in trade, energy, and sustainability policies, coupled with geopolitical tensions, will have significant ripple effects on market dynamics, causing price volatility.”

Operational Highlights

Upstream output grew by 6% year-on-year, with modest increase in downstream volume despite volatile global economic environment
Upstream output grew by 6% year-on-year, with modest increase in downstream volume despite volatile global economic environment

GAR has continued replanting its old estates as part of the Company’s long-term yield improvement initiative. As a result, GAR’s planted area as of 30 September 2025 declined slightly to around 531,000 hectares, of which 491,000 hectares were mature. Nucleus and plasma estates made up 414,000 and 117,000 hectares of this area, respectively.

Fruit yield for the nine months of 2025 rose by 6% year on year from 12.8 to 13.6 tonnes per hectare supported by favourable weather conditions. This translated into a total fruit output of 6.7 million tonnes, with a corresponding increase in palm product output of 6% to almost 2.0 million tonnes.

The Company’s downstream business continued to make progress amidst a volatile global economic environment. While competitive market conditions have constrained downstream performance, GAR’s merchandising volumes have continued to rise over the last two quarters, resulting in increased sales volume for the nine-month period.

The Company will continue to strengthen its competitive edge through value-added products tailored to customer demands for functionality, quality and sustainability; anticipating factors that may influence price trends and trade flows while continuing to deliver on its commitments to responsible production.

Investment in Sustainability

GAR continues to advance its sustainability ambitions under the Company’s Collective for Impact commitments. GAR has commissioned three new methane capture plants at its mills in 2025, targeting annual CO₂e reductions of 150,000 tonnes from its Scope 1 emissions.

The Company has surpassed 2025 targets for its flagship independent smallholder programme Sawit Terampil, reaching 11,000 farmers by the end of September 2025. The programme helps smallholders to improve productivity, meet regulatory requirements, and access sustainable markets through recognised sustainability certification schemes. Almost 300 participants were awarded Roundtable on Sustainable Palm Oil certification at the organisation’s recent Roundtable Conference, bringing the total number of smallholders certified to 800.

At the recent Asia Sustainability Reporting Awards, GAR’s commitment to transparency and quality reporting was recognised with the Platinum Award for Supply Chain Reporting and the Bronze Award for Environmental Impact Reporting. These recognitions reaffirm GAR’s dedication to transparent and credible sustainability disclosures aligned with leading reporting standards.

About Golden Agri-Resources Ltd (GAR)

GAR is a leading fully-integrated agribusiness company. In Indonesia, it manages an oil palm plantation area of approximately 531,000 hectares (including plasma smallholders) as of 30 September 2025. It has integrated operations focused on the technology-driven production and distribution of an extensive portfolio of palm-based products throughout its established international marketing network.

Founded in 1996, GAR was listed on the Singapore Exchange in 1999 and has a market capitalisation of US$2.9 billion as of 30 September 2025. Flambo International Limited, an investment company, is GAR’s largest shareholder, with a 50.56% stake. In addition, GAR’s subsidiary, PT SMART Tbk was listed on the Indonesia Stock Exchange in 1992.

As an integrated agribusiness, GAR delivers an efficient end-to-end supply chain, from responsible production to global delivery. In Indonesia, its primary activities include cultivating and harvesting oil palm trees; the processing of fresh fruit bunch into crude palm oil (CPO) and palm kernel; refining CPO into value-added products such as cooking oil, margarine, shortening, biodiesel and oleo-chemicals; as well as merchandising palm products globally.

GAR’s products are delivered to a diversified customer base in over 110 countries through its global distribution network with shipping and logistics capabilities, destination marketing, on-shore refining and ex-tank operations. GAR also has complementary businesses such as soybean-based products in China, sunflower-based products in India, and sugar businesses.

Agoda Unveils Trending Camping Destinations Among South Korean Travelers This Fall

By
Advertorial Desk
-

SEOUL, South Korea, Nov. 13, 2025 /PRNewswire/ — With the number of domestic campers estimated to exceed 7 million according to the Korea Tourism Organization (KTO), digital travel platform Agoda unveiled a ranking of the five most popular domestic camping destinations among South Korean travelers this fall based on booking data, with Jeju taking the crown.

Based on domestic bookings made on Agoda for accommodation types including tents, holiday and caravan parks, and farm stays during the cool fall-weather months of September to November, Jeju, Jeonju, and Gangneung ranked in the top three destinations among South Korean travelers. Samcheok and Namhae followed, rounding out the top five domestic camping destinations.

One of Gangneung’s campsites was listed among the top 10 domestic camping spots in the “Must-Visit Camping Map” curated by the KTO and Kakao Mobility, highlighting the city’s appeal as a premier camping destination.

Meanwhile, Namhae is emerging as a trending campsite with the “2025 Treasure Island Namhae Romantic Camping Festa,” held from September to November. The event offers unique programs that foster a camping culture, which supports local communities and encourages travelers to revisit.

South Koreans are also seeking out camping-style accommodation experiences beyond borders. Bali and Lombok (Indonesia) topped the list of most popular international camping destinations among South Korean travelers according to booking data on Agoda, followed by Pienza (Italy), Phuket (Thailand), and Majorca (Spain). Notably, Lombok has attracted attention among South Korean travelers after being featured on the reality TV show “Youn’s Kitchen,” showcasing the crystal-clear beaches and lush forests, while Pienza drew campers following its appearance on the TV show “Europe Outside Your Tent.”

Jay Lee, Regional Director, North Asia at Agoda, said, “Camping has become a popular form of relaxation and everyday enjoyment, with diverse styles such as traditional outdoor camping and glamping gaining traction. Agoda enables travelers to explore a wide range of accommodations from tents to caravan and holiday parks, making it easier to plan a camping experience that best suits their preferences.”

Travelers looking for the perfect camping or outdoor stays can start their search on Agoda to select from over 6 million holiday properties, more than 130,000 flight routes, and over 300,000 activities, all easily combined in a single booking. Discover the best deals on Agoda’s mobile app and visit Agoda.com for more information.

EdHeroes Awards 2025 Honoring Education Changemakers in Singapore

By
Advertorial Desk
-

SINGAPORE, Nov. 13, 2025 /PRNewswire/ — EdHeroes, a global network dedicated to improving education, hosted the EdHeroes Awards 2025 on November 5th, 2025 in Singapore, uniting influential leaders, educators, philanthropists, entrepreneurs, and non-profit organizations who are committed to shaping the future of learning and driving systemic reform across Southeast Asia and beyond.

Left to Right: Jason Ng (ALLiN Technologies), Alina Baimen (CEO and Co-founder of EdHeroes), HRH Mangkoenagoro X, and Farhannisa Nasution (Expansion Director of EdHeroes) during EdHeroes Awards 2025, Glass Dome, Singapore (5/11/2025).
Left to Right: Jason Ng (ALLiN Technologies), Alina Baimen (CEO and Co-founder of EdHeroes), HRH Mangkoenagoro X, and Farhannisa Nasution (Expansion Director of EdHeroes) during EdHeroes Awards 2025, Glass Dome, Singapore (5/11/2025).

The awarding ceremony was attended by His Royal Highness Mangkoenagoro X of Mangkunegaran Palace of Surakarta, Central Java, Indonesia. His Royal Highness, who is also a recipient of the Honorary Award for Contribution to Cultural Preservation and Education, highlighted the challenges emerging in education such as inequality, cultural loss, and the digital divide can be tackled with collaborative efforts. “As we say in Javanese Philosophy, “Urip iku urup”, meaning to live is to give light. Let us continue to give light through knowledge, through compassion, and through collaboration, so from heritage to horizon, we may guide the world toward a brighter, wiser, and more peaceful future,” he emphasized.

In collaboration with ALLiN Technologies, Preschool Market, IECCS, Brands For Good, and The Saturday Movement, the evening featured a forward-looking panel discussion with Katarina Ueltschi (Managing Director of BERNINA), Bruce Liew (Senior Director, Disability & Inclusion of AWWA), Grace Chew (Director of Creative and Community at PayPan and Glassdome), and Dr. Lillian Koh (Founder & Chair of the Fintech Academy).

List of EdHeroes Awards 2025 Nominations and their Winners:

Award Winners:

  • Environmental Education Visionary: Terra SG
  • Early Childhood Education Excellence: New Life Preschool
  • Support for Young Talents: EB Impact
  • Equity and Inclusion in Education: Movement for the Intellectually Disabled of Singapore (MINDS)
  • Parent and Family Engagement: Tzu-Chi Foundation Singapore
  • Lifelong Learning Initiative: NICE Global

Honorary Awards Recipients:

  • Technology and Innovation in Education: Saikr (赛氪)
  • Rural Areas Education: Saturday Movement 
  • STEM Education Innovator: Preschool Market
  • Contribution to Cultural Preservation and Education: His Royal Highness Mangkoenagoro X of Mangkunegaran Palace of Surakarta, Central Java, Indonesia

You can access the full stories and pictures from the EdHeroes Awards 2025 here.

Ascletis Announces Co-formulation of ASC36, Once-Monthly Next-Generation Amylin Receptor Agonist and ASC35, Once-Monthly Next-Generation GLP-1R/GIPR Dual Agonist for Clinical Development

By
Advertorial Desk
-

–  Using Ascletis’ proprietary Ultra-Long-Acting Platform technology, co-formulation of ASC36, a once-monthly subcutaneously administered amylin receptor peptide agonist and ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist, demonstrated a comparable pharmacokinetic (PK) profile to ASC36 and ASC35 dosed alone in head-to-head non-human primate studies.

–  ASC36 monotherapy demonstrated approximately 32% greater relative body weight reduction compared to eloralintide monotherapy in a head-to-head diet-induced obese (DIO) rat study, while ASC35 monotherapy demonstrated approximately 71% greater relative body weight reduction compared to tirzepatide monotherapy in a head-to-head DIO mouse study.

–  Co-formulation of ASC36 and ASC35 demonstrated approximately 51% greater relative body weight reduction compared to the co-formulation of eloralintide and tirzepatide in a head-to-head DIO rat study.

–  Co-formulation of ASC36 and ASC35 had excellent chemical and physical stability with no aggregation or precipitation caused by fibrillation at neutral pH.

–  Submission of an Investigational New Drug Application to the U.S. Food and Drug Administration for co-formulation of ASC36 and ASC35 is expected in the second quarter of 2026.

–  The Company will host a conference call in Mandarin at 10:00 a.m. China Standard Time on November 13, 2025. 

HONG KONG, Nov. 13, 2025 /PRNewswire/ — Ascletis Pharma Inc. (HKEX: 1672, “Ascletis”) announces the co-formulation of ASC36, a once-monthly next-generation amylin receptor agonist and ASC35, a once-monthly next-generation GLP-1R/GIPR dual agonist for clinical development. Ascletis expects to submit an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for co-formulation of ASC36 and ASC35 for the treatment of obesity in the second quarter of 2026.

Both ASC36, a once-monthly next-generation amylin receptor agonist, and ASC35, a once-monthly next-generation GLP-1R/GIPR dual agonist, were discovered and developed in-house utilizing Ascletis’ Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies. Ascletis has successfully co-formulated ASC36 and ASC35 in the proprietary ultra-long-acting formulation to enable once monthly subcutaneous (SQ) administration using its ULAP technology. Co-formulation of ASC36 and ASC35 had excellent chemical and physical stability with no aggregation or precipitation caused by fibrillation at neutral pH. Some of amylin receptor peptide agonists aggregate or precipitate at neutral pH, which leads to loss of potency, turbidity/particles, device clogging, and higher immunogenicity risk.

In head-to-head non-human primate (NHP) studies, co-formulation of ASC36 and ASC35 demonstrated a comparable pharmacokinetic profile to ASC36 and ASC35 dosed alone, supporting once-monthly SQ dosing.

ASC36 monotherapy demonstrated approximately 32% greater relative body weight reduction compared to eloralintide monotherapy in a head-to-head diet-induced obese (DIO) rat study. ASC35 monotherapy demonstrated approximately 71% greater relative body weight reduction compared to tirzepatide monotherapy in a head-to-head DIO mouse study (press release). The co-formulation of ASC36 and ASC35 demonstrated approximately 51% greater relative body weight reduction compared to the co-formulation of eloralintide and tirzepatide in a head-to-head DIO rat study (Table 1).

Table 1. ASC36 monotherapy and co-formulation of ASC36 and ASC35 demonstrated statistically and significantly more weight loss than eloralintide monotherapy and the co-formulation of eloralintide and tirzepatide in DIO rats after 7-day treatment

Group

Dosing

Total body weight change
from baseline

Greater relative weight
loss versus eloralintide
monotherapy or co-
formulation of eloralintide
and tirzepatide

Obese rats treated
with vehicle

Vehicle,

SQ, Q2D

-0.5 %

–

Obese rats treated
with ASC36
monotherapy

5 nmol/kg,

SQ, Q2D

-9.6%

(p =0.028 vs eloralintide
monotherapy)

32%

(vs eloralintide
monotherapy)

Obese rats treated
with eloralintide
monotherapy

5 nmol/kg,

SQ, Q2D

-7.3 %

–

Obese rats treated
with co-formulation
of ASC36 and
ASC35

5 nmol/kg
ASC36/8
nmol/kg ASC35,

SQ, Q2D

-14.5%

(p <0.0001 vs eloralintide
monotherapy; p <0.0001
vs co-formulation of
eloralintide and
tirzepatide)

99%

(vs eloralintide
monotherapy)

 

51%

(vs co-formulation of
eloralintide and
tirzepatide)

Obese rats treated
with co-formulation
of eloralintide and
tirzepatide

5 nmol/kg
eloralintide/8
nmol/kg
tirzepatide,

SQ, Q2D

-9.6 %

–

Note: DIO rats/obese rats: diet-induced obese rats; SQ: subcutaneous; Q2D: once every two days. 

“Based on these encouraging preclinical data, we believe the co-formulation of ASC36 and ASC35 has the potential to lead to greater weight loss reduction in people with obesity than single-agent therapies can achieve alone,” said Jinzi Jason Wu, Ph.D., Founder, Chairman and CEO of Ascletis, “The growing body of evidence reinforces our platform technologies’ ability to design, optimize and develop multiple once-monthly SQ ultra-long-acting peptides.”

Monotherapy and Co-formulation Therapies with ASC36

Ascletis is developing ASC36 as the cornerstone of its once-monthly therapies for the treatment of cardio-metabolic diseases including obesity. With the potential for better efficacy and improved tolerability to GLP-1 therapies, ASC36 is an ideal drug candidate to develop as a monotherapy and co-formulations with other long-acting agents such as ASC35 and potentially ASC47, an adipose-targeted thyroid hormone receptor beta (THRβ) agonist. 

Ascletis’ AISBDD and ULAP technologies enable the Company to design, optimize and develop multiple once-monthly SQ ultra-long-acting peptides, including ASC35 and ASC36. Based on the properties of peptides, the Company can design, through its proprietary ULAP technology, various slow-release constants (k) for peptides in SQ depots to precisely release injected peptides over desired dosing intervals to reduce peak-to-trough ratios and improve clinical outcomes.

Conference Call

Ascletis will host a conference call in Mandarin at 10:00 a.m. China Standard Time on November 13, 2025. A live webcast of the call will be available via Tencent Meeting/ VooV Meeting, with the Meeting ID: 573-120-481, or access links of:

Chinese Mainland: https://meeting.tencent.com/dm/uIyhG5Mtu3op; or

International: https://voovmeeting.com/dm/uIyhG5Mtu3op.

About Ascletis Pharma Inc.

Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases. Utilizing its proprietary Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies, Ascletis has developed multiple drug candidates in-house, including both small molecules and peptides, such as its lead program, ASC30, a small molecule GLP-1R agonist designed to be administered once daily orally and once monthly to once quarterly subcutaneously as a treatment therapy and a maintenance therapy for chronic weight management; ASC36, a once-monthly subcutaneously administered amylin receptor peptide agonist and ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist for chronic weight management. Ascletis is listed on the Hong Kong Stock Exchange (1672.HK).

For more information, please visit www.ascletis.com.

Contact：

Peter Vozzo
ICR Healthcare
443-231-0505 (U.S.)
Peter.vozzo@icrhealthcare.com 

Ascletis Pharma Inc. PR and IR teams
+86-181-0650-9129 (China)
pr@ascletis.com
ir@ascletis.com 

Cloocus Recognized as a Finalist for the 2025 Microsoft Partner of the Year – Gaming

By
Advertorial Desk
-

SEOUL, South Korea, Nov. 13, 2025 /PRNewswire/ — Cloocus today announced it has been named a finalist for the 2025 Microsoft Partner of the Year Award (Gaming). The company was honored among a global field of top Microsoft partners for demonstrating excellence in innovation and implementation of customer solutions based on Microsoft technology.

(Image: Winner Microsoft Partner of the Year)
(Image: Winner Microsoft Partner of the Year)

Steve Hong, CEO of Cloocus, stated, “Over the past six years, Cloocus has achieved multiple recognitions in partnership with Microsoft. However, this year’s achievement is particularly meaningful as it reflects our capabilities and competitiveness among leading global partners.”

He added, “Cloocus is currently expanding its business across Korea, Japan, Malaysia, and the United States, and we plan to demonstrate the strength of a Korean AI-driven company in even more markets around the world.”

The Microsoft Partner of the Year Awards recognize Microsoft partners that have developed and delivered outstanding Microsoft Cloud applications, services, devices, and AI innovation during the past year. Awards were classified in various categories, with honorees chosen from more than 4,600 nominations across more than 100 countries.

Cloocus was recognized for providing outstanding solutions and services in Gaming.

Cloocus has been a leading Microsoft Azure partner driving cloud transformation in the gaming industry, serving major game customers such as Krafton, Pearl Abyss, and Netmarble.

In an environment where gaming companies require advanced capabilities – such as real-time global operations, large-scale traffic handling, and differentiated player experiences – Cloocus delivers AI-powered managed services that help customers adopt Microsoft’s latest technologies, including Azure OpenAI, Microsoft Sentinel, and Microsoft Copilot. From tailored proof-of-concept engagements to fully integrated operations, Cloocus supports the end-to-end modernization of each customer’s environment. The high-performance cloud, AI, and security expertise proven in gaming is now serving as a strong foundation for accelerating cloud migration and AI adoption across other enterprise sectors, including manufacturing, retail, and healthcare.

Cloocus continues to expand Azure-based AI, data, and security services for leading gaming and enterprise customers, while strengthening joint go-to-market motion and project collaboration with Microsoft.

Cloocus was recognized as the Microsoft Partner of the Year in Korae for three consecutive years from 2021 to 2023. This year, the recognition has extended to the global level-demonstrating not only Cloocus’s technical capabilities but also its ability to scale solutions across industries and deliver globally referenceable outcomes.

“Congratulations to all the winners and finalists of the 2025 Microsoft Partner of the Year Awards”, said Nicole Dezen, Chief Partner Officer and Corporate Vice President at Microsoft. “This year, our partners harnessed the transformative power of Microsoft’s Cloud and AI platforms to deliver transformative solutions that redefine the boundaries of innovation. The energy and ingenuity across our ecosystem continue to inspire us. The 2025 honorees exemplify what’s possible when technology and vision unite to empower customers around the world.”

The 2025 Microsoft Partner of the Year Awards are announced ahead of Microsoft Ignite, which will be held in San Francisco from November 18-21. Additional details on the 2025 awards are available on the Microsoft Partner blog: https://aka.ms/2025POTYA_Announcement. The complete list of categories, winners and finalists can be found at https://aka.ms/2025POTYAWinnersFinalists. 

Appian Launches New AI Capabilities To Automate Complex Work & Accelerate App Modernisation

By
Advertorial Desk
-

Proven in successful customer trials, new platform capabilities embed powerful agents into processes and empower business users to modernise legacy apps with ease.

SYDNEY, NSW, Nov. 13, 2025 /PRNewswire/ — Appian (Nasdaq: APPN), a leader in AI-powered process automation, today announced platform enhancements that embed powerful AI agents directly into enterprise processes. The latest Appian Platform release delivers practical, measurable value by making AI more than just an assistant.

Proven in successful customer trials, new platform capabilities embed powerful agents into processes and empower business users to modernize legacy apps with ease.
Proven in successful customer trials, new platform capabilities embed powerful agents into processes and empower business users to modernize legacy apps with ease.

Agents directly embedded in business processes

Agent Studio allows organisations to deploy Appian’s most powerful AI agents yet at scale. These agents can reason, handle unexpected conditions, and act on enterprise data to automate complex work. Appian agents are powerful because they inherit critical platform properties like complete data access, process context and guardrails. With Agent Studio, business users can use natural language to define high-level goals. Then, AI agents use Appian’s data fabric and tools to determine the most effective path forward. With a complete view of enterprise data, agents make smarter decisions, interpret unstructured data from varied sources, and make real-time adjustments. Appian agents are embedded into process, enabling easy governance and auditability of agent behavior.

Agent Studio is now generally available. Following its preview at Appian World in April 2025, customer interest was overwhelming. Early users validated Agent Studio’s enterprise readiness and ease of use in a market challenged with failed agent projects. One hundred percent of beta program participants found Agent Studio ‘intuitive or very intuitive.’

“Agent Studio has empowered our team to rapidly prototype intelligent agents that automate task routing based on regulatory rules and orchestrate relevant workflows. The ability to combine rule-based logic with AI-driven insights for smarter routing is a major advantage,” said Johnnie Jo, Development Technical Lead, NIISQ. “We plan to continue leveraging Appian Agent Studio to drive innovation and efficiency.”

AI-powered application modernisation: from idea to app in minutes

Appian Composer is now generally available, and more than 130 organisations have already built over 1,300 applications using the tool. Composer transforms how organisations modernise applications, allowing users with any level of development expertise to turn ideas into working applications fast with an AI-guided experience. Composer builds an interactive plan for the user stories, data, processes and user experiences for the application. Composer gives business, IT, and AI a collaborative workspace to work together to plan and design the application. Then, with a click of a button, you can generate your application ready to be further tailored to business needs.

Data Fabric enhancements

Appian’s industry-leading data fabric can now handle up to 50 million rows with 5x faster write throughput. Data Fabric supports enhanced information security compliance via transparent data encryption.

“Many organisations deployed ineffective and expensive, stand-alone AI chatbots in their back-office operations teams,” said Michael Beckley, CTO, Appian. “Research from MIT shows that approach fails 95% of the time because AI on its own is easily confused by different data contexts. Appian takes a fundamentally different path. We embed specialised AI Agents directly inside operations workflows where they deliver reliable results at massive scale, enabling real-world outcomes, like accurately processing tens of millions insurance quotes per year for one customer.”

By integrating AI into workflows, enterprises can move beyond isolated pilots to scalable, governed AI initiatives. To learn how to make AI part of your processes, visit https://ap.pn/47IOCAr.

*Source: “The GenAI Divide: State of AI in Business 2025,” MIT Project NANDA, July 2025.

About Appian

Appian provides a platform for AI-powered process automation that’s built for mission critical operations. Committed to client success, we serve many of the world’s largest companies across all major industries. For more information, visit appian.com. [Nasdaq: APPN]

Follow Appian: LinkedIn, X (Twitter)

Photo – https://laotiantimes.com/wp-content/uploads/2025/11/appian_new_ai_capabilities.jpg
Logo – https://laotiantimes.com/wp-content/uploads/2025/11/appian_caption_2700px_logo.jpg

Laronix Secures $3.2 Million Grant from the Australian Government to Bring its AI-Powered Voice Technology to the Market

By
Advertorial Desk
-

BRISBANE, Australia, Nov. 13, 2025 /PRNewswire/ — Laronix, (“Laronix” or the “Company”), a commercial-stage medical technology (MedTech) company and an industry-leading innovator in voice restoration technologies, today announced that it has been awarded AUD $3.2 million (approximately USD $2.1 million) in non-dilutive funding from the Australian Government’s Industry Growth Program (IGP 2025).

Patient Using Laronix MIRA Voice Device
Patient Using Laronix MIRA Voice Device

Farzaneh Ahmadi, PhD, Chief Executive Officer of Laronix, said, “Human voice loss is a largely unattended global health problem afflicting millions of patients every year. Laronix specializes in developing next-generation voice technologies and innovative artificial larynx devices that bring the gift of natural-sounding voice to voiceless patients. We are deeply grateful for the Australian government’s support through the IGP 2025, as it will enable us to accelerate the development of the Laronix MIRA Voice product line and bring this transformative solution to the market over the next two years.”

Laronix’s first product, AVA Voice, is commercially available in the U.S. and Australia, and it enables permanent voice-loss (laryngectomy) patients to speak and sing with exceptionally high-quality voices. AVA Voice continues to gain strong clinical and patient satisfaction and is already being used in over 40 leading hospitals across both regions.

Building on AVA’s success, Laronix is expanding its product line with MIRA Voice, a smart and non-invasive artificial larynx capable of restoring natural-sounding voice for the broader voice-loss indications, including the millions of patients who lose their voice as a result of intubation in intensive care units (ICUs), as well as patients with neurological conditions such as Parkinson’s Disease. Laronix is also developing MIRA-AI, the Company’s latest offering, which effectively creates an ultra-realistic voice for the patient using advanced AI, which is strikingly similar to their original natural-sounding voice.

Laronix’s IGP 2025 project, “MIRA Voice – a game-changing technology for human voice loss,” aims to accelerate MIRA Voice’s development from functional prototypes to clinical testing, adoption, and commercial launch. Mousa Ahmadi, Laronix’s Chief Operating Officer, added, “The market demand and patients’ and clinicians’ response to MIRA Voice have been overwhelmingly positive. Laronix has managed to secure collaborations with several world-leading hospitals for MIRA’s product adoption. The IGP grant enables us to scale MIRA Voice adoption in different markets faster and bring this much-needed innovation to the millions of patients who need it most.”

About IGP 2025

The Australian Government’s Industry Growth Program provides Australia’s high-potential innovation companies with matched funding to accelerate the commercialization of breakthrough technologies. For more information on IGP 2025: https://business.gov.au/grants-and-programs/industry-growth-program/grant-recipients

About Laronix

Laronix is an ISO-13485 certified MedTech company specializing in advanced AI-powered voice restoration technologies for patients with permanent, chronic, and acute voice loss in an over USD$5 billion market. The Company is headquartered in Brisbane, Australia, with commercial operations in New York, U.S. For more information, visit:  www.laronix.com.

Laronix Inc.
44 South Broadway, Suite 100
White Plains, NY 10601
USA
info@laronix.com

Laronix Australia
167 Eagle Street, Floor 9,
Brisbane City, Queensland 4000
Australia

Media Contact
Farzaneh Ahmadi
farzane@laronix.com  

1...1,8271,8281,829...6,467Page 1,828 of 6,467